Evidence map›Paper›PMID 28228278›Full record

ReviewImmunity2017

Immunopathogenesis of Rheumatoid Arthritis.

Gary S Firestein, Iain B McInnes

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Immunity, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 647 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
647citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

647 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Structure-Based Engineering for PTPσ-Targeted Therapeutic Development.International journal of molecular sciences · 2026
    Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

587 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Gary S FiresteinUniversity of California San Diego, La Jolla, CA 92093, USA. Electronic address: gfirestein@ucsd.edu.
Iain B McInnesInstitute of Infection Immunity and Inflammation, University of Glasgow, Glasgow G128QQ, UK. Electronic address: iain.mcinnes@glasgow.ac.uk.

Funding

Identification of key regulators in rheumatoid arthritisR01AR065466 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, WANG, WEI · 2014 to 2024
$4.6M
Regulation of p38 and inflammation by MAPK kinasesR01AI070555 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S · 2006 to 2016
$3.8M
Medical Research Council MR/N005813/1NIAID NIH HHS R01 AI070555NIAMS NIH HHS R01 AR065466
6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is the most common inflammatory arthropathy. The majority of evidence, derived from genetics, tissue analyses, models, and clinical studies, points to an immune-mediated etiology associated with stromal tissue dysregulation that together propogate chronic inflammation and articular destruction. A pre-RA phase lasting months to years may be characterized by the presence of circulating autoantibodies, increasing concentration and range of inflammatory cytokines and chemokines, and altered metabolism. Clinical disease onset comprises synovitis and systemic comorbidities affecting the vasculature, metabolism, and bone. Targeted immune therapeutics and aggressive treatment strategies have substantially improved clinical outcomes and informed pathogenetic understanding, but no cure as yet exists. Herein we review recent data that support intriguing models of disease pathogenesis. They allude to the possibility of restoration of immunologic homeostasis and thus a state of tolerance associated with drug-free remission. This target represents a bold vision for the future of RA therapeutics.

Indexed as

AnimalsArthritis, RheumatoidHumans

Identifiers

PMID28228278
PMCPMC5385708

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.